{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Frationale-parpi-combinations-S7LzyQww","width":444,"version":"1.0","type":"rich","title":"Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/66714106-0a6b-4b89-80b9-cfdee176145e/prostate-tm-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/bc9e8536-6dec-4c4b-a911-85759e1e55a1\" height=\"200\" width=\"100%\" title=\"Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast episode, listen to medical oncologists Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the rationale for using PARP inhibitors in combination with other therapies for prostate cancer."}